CD274 and bladder transitional cell carcinoma: Then, we further calculated the TS score for BLCA patients in the immunotherapy cohort (Imvigor210) and found that BLCA patients from the low TS score group had a better prognosis and higher reaction rate to PD-L1 inhibitor treatment than patients from the high TS score group (Fig. 7D–F).